Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.

Nature communications - 1 Jan 2013

Baraban Scott C, Dinday Matthew T, Hortopan Gabriela A

Abstract excerpt

Dravet syndrome is a catastrophic pediatric epilepsy with severe intellectual disability, impaired social development and persistent drug-resistant seizures. One of its primary monogenic causes are mutations in Nav1.1 (SCN1A), a voltage-gated sodium channel. Here we characterize zebrafish Nav1.1 (scn1Lab) mutants originally identified in a chemical mutagenesis screen. Mutants exhibit spontaneous abnormal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Benzimidazoles
Share to Diazepam

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Epilepsies, Myoclonic

Share to NAV1.1 Voltage-Gated Sodium Channel

Share to Seizures

Share to Valproic Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 24002024
DOI: 10.1038/ncomms3410
PMCID: PMC3891590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment.PMID 24002024Read ↗

Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndromeSemantic proximity Read ↗

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet SyndromeSemantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype and epileptiform activity in a novel zebrafish model for Dravet Syndrome.Semantic proximity Read ↗

Testing of putative antiseizure drugs in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

NaV1.1 and NaV1.6 selective compounds reduce the behavior phenotype in a novel zebrafish model for Dravet SyndromeSemantic proximity Read ↗

Testing of putative antiseizure medications in a preclinical Dravet syndrome zebrafish modelSemantic proximity Read ↗

Behavioral Comorbidities and Drug Treatments in a Zebrafish scn1lab Model of Dravet Syndrome.Semantic proximity Read ↗

Phenotype-based screening of synthetic cannabinoids in a Dravet Syndrome zebrafish modelSemantic proximity Read ↗

New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndromeSemantic proximity Read ↗

Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish ModelSemantic proximity Read ↗

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist FenfluramineSemantic proximity Read ↗

Drug repurposing for Dravet syndrome in scn1Lab−/− mutant zebrafishSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.